three-phase investigational new drug process (Phase I: establish drug safety and pharmacokinetics; Phase II: establish therapeutic efficacy and dosage range; Phase III: comparative clinical trials ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
Gain Therapeutics (GANX) announced the dosing of the first participant with Parkinson’s disease in its Phase 1b clinical trial of GT-02287, the ...
Third Arc Bio Inc., a clinical stage biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, today announced the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results